<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803556</url>
  </required_header>
  <id_info>
    <org_study_id>CA201-001</org_study_id>
    <secondary_id>KDG 132</secondary_id>
    <nct_id>NCT00803556</nct_id>
  </id_info>
  <brief_title>Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy</brief_title>
  <official_title>Phase 1 Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the Maximally Tolerable Dose (MTD) of KOS-1022 when administered weekly in&#xD;
      combination with trastuzumab or in combination with trastuzumab and paclitaxel to patients&#xD;
      with advanced solid tumor malignancies&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Dose Limiting Toxicities</measure>
    <time_frame>During Cycle 1 (4-weeks in duration)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Summary of Adverse Events, Serious Adverse Events, Deaths and Discontinuations due to Adverse Events</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Clinical Laboratory Abnormalities</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of KOS-1022 and its metabolites</measure>
    <time_frame>Week 1 and Week 4: pretreatment, 30 and 55 minutes after start of infusion, 5, 15, 30 minutes and 1, 2, 4, 6, 24, 72 hours post-infusion; Weeks 2 and 3: pre-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of KOS-1022 and its metabolites</measure>
    <time_frame>Week 1 and Week 4: pretreatment, 30 and 55 minutes after start of infusion, 5, 15, 30 minutes and 1, 2, 4, 6, 24, 72 hours post-infusion; Weeks 2 and 3: pre-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-Half of KOS-1022 and its metabolites</measure>
    <time_frame>Week 1 and Week 4: pretreatment, 30 and 55 minutes after start of infusion, 5, 15, 30 minutes and 1, 2, 4, 6, 24, 72 hours post-infusion; Weeks 2 and 3: pre-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of Hsp90-client proteins in peripheral blood lymphocytes</measure>
    <time_frame>Pretreatment, 4 hours following the Day 1 KOS-1022 infusion, Day 2, Day 4; pretreatment samples Weeks 2 and 3; pretreatment, 4 hours following the Day 22 KOS-1022 infusion, Day 23, Day 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response as assessed by RECIST criteria first after two cycles of therapy</measure>
    <time_frame>For patients with measurable disease, response will be assessed by RECIST criteria first after two cycles of therapy (8 weeks in patients having no delay in the schedule of administration)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients whose last dose is &gt; 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin&#xD;
Patients whose last dose is &lt; 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients whose last dose is &gt; 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of paclitaxel and 60 min of infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin&#xD;
Patients whose last dose is &lt; 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alvespimycin</intervention_name>
    <description>Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>BMS-826476</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Herceptin</other_name>
    <other_name>BMS-722782</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Solution, IV, 60-90 mg/m2, weekly until disease progression or DLT</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Taxol</other_name>
    <other_name>BMS-181339</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  KPS performance status &gt;= 70%&#xD;
&#xD;
          -  Schedule A: all patients must have a histologically confirmed solid tumor malignancy.&#xD;
             Schedule B: patients must have metastatic breast cancer with Her2 amplification by&#xD;
             FISH or 3+ Her2 overexpression by immunohistochemistry (&quot;IHC&quot;). Patients are not&#xD;
             required to have measurable disease for this investigation. Disease must be assessed&#xD;
             within 28 days prior to treatment initiation&#xD;
&#xD;
          -  All Adverse Events of any prior chemotherapy, surgery, or radiotherapy, must have&#xD;
             resolved to NCI CTCAE (v. 3.0) Grade &lt;= 2 (except for alopecia)&#xD;
&#xD;
          -  The following laboratory results, within 10 days of KOS-1022 administration:&#xD;
&#xD;
               -  Hemoglobin &gt;= 8.5 g/dL&#xD;
&#xD;
               -  Absolute neutrophils count &gt;= 1.5 x 10*9* /L&#xD;
&#xD;
               -  Platelet count &gt;= 75 x 10*9*/L&#xD;
&#xD;
               -  Serum bilirubin &lt;= 2 x ULN&#xD;
&#xD;
               -  AST and ALT &lt;= 2.5 x ULN&#xD;
&#xD;
               -  Serum creatinine &lt;= 2 x ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented hypersensitivity reaction of CTCAE Grade &gt;= 3 to prior therapy containing&#xD;
             trastuzumab&#xD;
&#xD;
          -  Pregnant or breast-feeding women. Male patients must be surgically sterile or agree to&#xD;
             use an acceptable method of contraception&#xD;
&#xD;
          -  Known active CNS metastases&#xD;
&#xD;
          -  Administration of any other chemotherapy, biological, immunotherapy or investigational&#xD;
             agent (therapeutic or diagnostic) within 14 days prior to receipt of study medication.&#xD;
             Patients should be 6 weeks from last dose of nitrosourea&#xD;
&#xD;
          -  Patients with Grade 2 or higher dyspnea at rest on room air; patients with other&#xD;
             clinically significant pulmonary co-morbidity(s) that might predispose the patient to&#xD;
             pulmonary toxicity&#xD;
&#xD;
          -  Moderately severe dry eye&#xD;
&#xD;
          -  Prior pulmonary toxic chemotherapy (e.g, bleomycin or carmustine)&#xD;
&#xD;
          -  Congestive heart failure, or a left ventricular ejection fraction (LVEF)&#xD;
&#xD;
          -  Any medical conditions that, in the Investigator's opinion, would impose excessive&#xD;
             risk to the patient&#xD;
&#xD;
          -  Patients with previous malignancies unless free of recurrence for at least 5 years&#xD;
             except cured basal cell carcinoma of the skin, carcinoma-in-situ of either the uterine&#xD;
             cervix or urinary bladder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Melvin &amp; Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <last_update_submitted>June 23, 2011</last_update_submitted>
  <last_update_submitted_qc>June 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

